ClinicalTrials.gg
CompletedNCT03359057Updated Dec 4, 2017

Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel

A Phase 3 interventional study of ethinyl estradiol + levonorgestrel + folic acid and Folic Acid in Contraception, sponsored by Galeno Desenvolvimento de Pesquisas Clínicas. Completed at 1 site in Brazil. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-04.

Sponsored by Galeno Desenvolvimento de Pesquisas Clínicas · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Feb 2013, registered Nov 2017).
Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This trial evaluated folic acid supplementation after oral administration of the ethinyl estradiol + levonorgestrel + folic acid (0.02 mg + 0.10 mg + 0.4 mg) coated tablet (Level-Fol® Biolab Sanus Farmacêutica, São Paulo, Brazil) in healthy female volunteers, based on statistical comparisons of folate levels in erythrocytes. Its safety and tolerability was also evaluated.

Read the detailed description

This Phase III trial was performed as a monocentric, open label, randomized design, with 1 treatment regimen, in 3 cycles (12 weeks), with administration in multiple doses, in which the healthy volunteers received one coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg (Level-Fol® Biolab Sanus Farmaceutica, Brazil) for 21 days and a placebo coated tablet containing folic acid 0.4 mg only (Biolab Sanus Farmaceutica, Brazil) on the last 7 days of the cycle.

The subjects were required to present to the Clinical Unit for every drug administration, which was assisted by a member of the research team. Blood samples of 15 mL were collected via direct venepuncture into tubes containing 50 µL of ethylenediaminetetraacetic acid (EDTA) at pre-dose, 1st, 21st, 28th, 29th, 49th, 56th, 57th, 77th and 84th day of treatment.

Te safety assessment was based on recording adverse events throughout the study duration as well as through the monitoring of vital signs and evaluation of laboratory tests and ECG.

02

Conditions studied

  • Contraception

Keywords

  • Folic acid
  • Supplementation
  • Ethinyl estradiol
  • Levonorgestrel
  • Oral contraceptive
03

In context

Lead sponsor

Galeno Desenvolvimento de Pesquisas Clínicas is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female volunteers aged between 18 and 35 years old (fertile age), without hormonal use at least 3 months (oral) or 1 year (injectable), regular cycle and no pregnant or breastfeeding;
  • (BMI) ≥ 19.0 kg/m² and ≤ 28.75 kg/m²
  • No evidence of significant diseases, that, at the investigator's discretion, may affect the participation in the clinical trial, in accordance with the protocol requirements
  • Ability to understand the nature and the objective of the clinical trial, including the risks and possible side effects; intention to cooperate with the investigator and act in accordance with the protocol requirements, as confirmed by the form signature.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known to the compounds of the products, severe allergies or multiple drug allergies
  • Existing diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the drug
  • Screening laboratory tests presenting deviations deemed as , which, due to possible risks, prevents the participation in clinical trial.
  • Use of maintenance therapy with any drug
  • Drug or alcohol dependence
  • Volunteers who ingests more than 5 cups of coffee or tea per day and/or smoke
  • Volunteers with unusual eating habits, e.g, vegetarian
  • Treatment, within 3 months prior to the initiation of the clinical trial treatment, with any drug known to have a well-established toxic potential to major organs.
  • Use of regular medication within 2 weeks before the start of treatment and the date of evaluation, or made use of any medication within one week, except for oral or cases where, based on the half-life of the drug and/or active metabolites, complete elimination can be assumed
  • Treatment within 6 months prior to the study with any known drug of have a well-defined toxic potential in large organs
  • Hospitalization for any reason up to 8 weeks before the start of the treatment of this study
  • Participation in a clinical trial during the last 6 months
  • Blood donation or other blood loss of more than 450 mL within the last 3 months
  • Pregnant, delivery or abortion in the 12 weeks prior to the planned hospitalization
  • The volunteer who has any condition that prevents him from participating in the study by judgment of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Estradiol + levonorgestrel + folic acid

    Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.

    Drug: ethinyl estradiol + levonorgestrel + folic acid

  • Placebo comparator
    Folic acid

    Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.

    Drug: Folic Acid

Interventions

  • Drugethinyl estradiol + levonorgestrel + folic acid

    Drug pages: Ethinyl Estradiol · Levonorgestrel · Folic Acid

    One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).

  • DrugFolic Acid

    One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).

06

What researchers measure

Primary outcomes

  1. Measurement of folate levels in erythrocytes.

    Blood sampling for the determination of erythrocyte levels of folate in the subjects after the treatment with the test drug or placebo.

    Time frame: 0-84 days

Secondary outcomes

  1. Number of adverse events

    Number of adverse events, including clinically relevant alterations of vital signs and laboratory tests results

    Time frame: 0-84 days

07

Study locations

1 site
  • Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
    Campinas, SP, Brazil
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Jul 2013, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 2, 2017
StartActual
Feb 26, 2013
Primary completionActual
Jul 4, 2013
CompletionActual
Sep 17, 2013
Last update
Dec 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03359057
Lead sponsor
Galeno Desenvolvimento de Pesquisas Clínicas
Collaborators
Biolab Sanus Farmaceutica
Responsible party
Gilberto De Nucci (Doctor, Galeno Desenvolvimento de Pesquisas Clínicas) — Principal investigator
First posted
Dec 2, 2017
Start date
Feb 26, 2013
Primary completion
Jul 4, 2013
Completion
Sep 17, 2013
Last update
Dec 4, 2017

Study contacts

Gilberto De Nucci, Doctor
principal investigator · Galeno Desenvolvimento de Pesquisas Clinicas Ltda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethinyl Estradiol · Levonorgestrel · Folic Acid

Start the discussion